Feb 23, 2023
Moderna Research:
https://abcnews.go.com/Health/
https://medicalxpress.com/
Ivermectin Research:
http://thehealthedge.com/
https://journals.plos.org/
https://www.medrxiv.org/
https://journals.sagepub.com/
https://papers.ssrn.com/sol3/
https://www.ncbi.nlm.nih.gov/
https://www.ijidonline.com/
https://fism.tv/peer-reviewed-
mRNA Shot Research:
https://www.telegraph.co.uk/
1. Exploring the relationship between all-cause and cardiac-related mortality following COVID-19 vaccination or infection in Florida residents - study conducted by the Surgeon General of Florida: Primary findings: “In the 28 days following vaccination, a statistically significant increase in cardiac-related deaths was detected for the entire study population (RI = 1.07, 95% CI = 1.03 - 1.12). Stratifying by age group revealed RIs were significantly higher for age groups 25 - 39 (RI = 2.16, 95% CI = 1.35 - 3.47) and 60 or older (RI = 1.05, 95% CI = 1.01 - 1.10).”
2. Clinical cardiovascular emergencies and the cellular basis of COVID-19 vaccination: Primary findings: “COVID-19 vaccines evoke rare but fatal thrombotic events, whereas messenger RNA\055based vaccines appear to be associated with risks of pericarditis/myocarditis, with the latter being more predominant in young adults following the second dose.”
https://www.ncbi.nlm.nih.gov/
3. Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series: Primary findings: “Myocarditis/myopericarditis and pericarditis were the most common adverse events among the 243 reported cardiac complications, post mRNA COVID-19 vaccination. Males with a median age of 21 years had the highest frequency of myocarditis.”
https://pubmed.ncbi.nlm.nih.
4. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: Primary findings: “…increased risk of myocarditis/pericarditis was associated with the second dose of BNT162b2 and both doses of mRNA-1273. The highest risks were observed in males of 12 to 39 years and in males and females 18 to 29 years vaccinated with mRNA-1273.”
https://pubmed.ncbi.nlm.nih.
5. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults: Primary findings: “Pfizer and Moderna mRNA COVID-19 vaccines were associated with an excess risk of serious adverse events of special interest of 10.1 and 15.1 per 10,000 vaccinated over placebo baselines of 17.6 and 42.2 (95 % CI −0.4 to 20.6 and −3.6 to 33.8), respectively.”
https://www.sciencedirect.com/
6. Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination: Primary findings: “Overall, autopsy findings indicated death due to acute arrhythmogenic cardiac failure. Thus, myocarditis can be a potentially lethal complication following mRNA-based anti-SARS-CoV-2 vaccination.”
https://link.springer.com/
7. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents Primary findings: “In a cohort study of 23.1 million residents across 4 Nordic countries, risk of myocarditis after the first and second doses of SARS-CoV-2 mRNA vaccines was highest in young males aged 16 to 24 years after the second dose. For young males receiving 2 doses of the same vaccine, data were compatible with between 4 and 7 excess events in 28 days per 100 000 vaccinees after second-dose BNT162b2, and between 9 and 28 per 100 000 vaccinees after second-dose mRNA-1273.”
https://jamanetwork.com/
8. Booster Vaccination with SARS-CoV-2 mRNA Vaccines and Myocarditis Risk in Adolescents and Young Adults: A Nordic Cohort Study of 8.9 Million Residents: Primary findings: “Our results suggest that a booster dose is associated with increased myocarditis risk in male adolescents and young male adults.”
https://www.medrxiv.org/
In addition to these studies, the FDA has cautioned that some COVID-19 vaccines carry the risk of myocarditis and pericarditis, especially in young men.
https://www.fda.gov/news-
Though not related to young men, on January 13, 2023, CDC cautioned that Pfizer/BioNTech’s Bivalent booster vaccine might increase the risk of ischemic stroke in people over 65, a condition in which blood clots of other particles block the blood vessels to the brain. While the concern relates to those over 65, this new safety signal illustrates that we do not know the mid- or long-term health outcomes of the COVID-19 vaccines.
Although some have suggested that myocarditis and pericarditis are elevated after a case of COVID-19, a large study of about 600,000 adults concludes that is not the case. The study, “The Incidence of Myocarditis and Pericarditis in Post COVID-19 Unvaccinated Patients-A Large Population-Based Study” stated, “We did not observe an increased incidence of neither pericarditis nor myocarditis in adult patients recovering from COVID-19 infection.”